BACKGROUND: Somatic mutations in the X-linked tumour suppressor gene WTX have been observed in 6- 30% of sporadic cases of Wilms tumour. Germline mutations in the same gene cause the sclerosing skeletal dysplasia, osteopathia striata congenita with cranial sclerosis (OSCS). No evidence points towards a susceptibility to the development of tumours in individuals with OSCS, suggesting that there are unrecognised additional determinants that influence the phenotypic outcome associated with germline mutations in WTX. One explanation may be that a somatic mutation in WTX may need to occur late in tumour development to contribute to tumourigenesis. METHODS: Here a panel of four sporadic Wilms tumours with associated nephrogenic rest tissue and characterised WTX and CTNNB1 mutations is studied to ascertain the temporal sequence of acquisition of these mutations. Additionally, a family with OSCS is described segregating a germline mutation in WTX and manifesting a lethal phenotype in males. One male from this family had bilateral multifocal nephrogenic rests at autopsy. RESULTS: In one of the four tumours the WTX mutation was present in both tumour and rest tissue indicating it had arisen early in tumour development. In the remaining three tumours, the WTX mutation was present in the tumour only indicating late acquisition of these mutations. CONCLUSIONS: These data indicate that WTX mutations can arise both early and late in Wilms tumour development. WTX mutations may predispose to nephrogenic rest development rather than Wilms tumour per se.
BACKGROUND: Somatic mutations in the X-linked tumour suppressor gene WTX have been observed in 6- 30% of sporadic cases of Wilms tumour. Germline mutations in the same gene cause the sclerosing skeletal dysplasia, osteopathia striata congenita with cranial sclerosis (OSCS). No evidence points towards a susceptibility to the development of tumours in individuals with OSCS, suggesting that there are unrecognised additional determinants that influence the phenotypic outcome associated with germline mutations in WTX. One explanation may be that a somatic mutation in WTX may need to occur late in tumour development to contribute to tumourigenesis. METHODS: Here a panel of four sporadic Wilms tumours with associated nephrogenic rest tissue and characterised WTX and CTNNB1 mutations is studied to ascertain the temporal sequence of acquisition of these mutations. Additionally, a family with OSCS is described segregating a germline mutation in WTX and manifesting a lethal phenotype in males. One male from this family had bilateral multifocal nephrogenic rests at autopsy. RESULTS: In one of the four tumours the WTX mutation was present in both tumour and rest tissue indicating it had arisen early in tumour development. In the remaining three tumours, the WTX mutation was present in the tumour only indicating late acquisition of these mutations. CONCLUSIONS: These data indicate that WTX mutations can arise both early and late in Wilms tumour development. WTX mutations may predispose to nephrogenic rest development rather than Wilms tumour per se.
Authors: Peter E Clark; Dina Polosukhina; Harold Love; Hernan Correa; Cheryl Coffin; Elizabeth J Perlman; Mark de Caestecker; Harold L Moses; Roy Zent Journal: Am J Pathol Date: 2011-10-08 Impact factor: 4.307
Authors: Annie Moisan; Miguel N Rivera; Sutada Lotinun; Sara Akhavanfard; Erik J Coffman; Edward B Cook; Svetlana Stoykova; Siddhartha Mukherjee; Jesse A Schoonmaker; Alexa Burger; Woo Jae Kim; Henry M Kronenberg; Roland Baron; Daniel A Haber; Nabeel Bardeesy Journal: Dev Cell Date: 2011-05-17 Impact factor: 12.270
Authors: Dina Polosukhina; Harold D Love; Hernan Correa; Zengliu Su; Kimberly B Dahlman; William Pao; Harold L Moses; Carlos L Arteaga; Harold N Lovvorn; Roy Zent; Peter E Clark Journal: Mol Oncol Date: 2017-03-15 Impact factor: 6.603
Authors: Alicia Bach; Jingyi Mi; Matthew Hunter; Benjamin J Halliday; Sixto García-Miñaúr; Francesca Sperotto; Eva Trevisson; David Markie; Ian M Morison; Marwan Shinawi; Daniel N Willis; Stephen P Robertson Journal: Eur J Hum Genet Date: 2020-09-02 Impact factor: 4.246